The pharmacological efficacy of BRAF inhibitors is limited to a subset of cancer patients with BRAF-mutated metastatic melanoma, because the durability of responses in BRAF-mutated melanoma is restricted by the onset of drug resistance mechanisms [11]. The gene discussed is BRAF; the disease is cancer.